+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bronchiectasis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, Bronchiectasis Type, Distribution Channel - Global Forecast to 2030- Product Image
Bronchiectasis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, Bronchiectasis Type, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Bronchiectasis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, Bronchiectasis Type, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011462
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bronchiectasis Drugs Market grew from USD 1.52 billion in 2024 to USD 1.65 billion in 2025. It is expected to continue growing at a CAGR of 9.22%, reaching USD 2.58 billion by 2030.

Understanding the Future of Bronchiectasis Therapeutics

Bronchiectasis, a chronic respiratory disorder characterized by irreversible dilation of the bronchi, presents a complex treatment landscape marked by persistent infections, inflammation, and mucus accumulation. Advances in drug development and a deeper understanding of the disease’s pathophysiology have catalyzed a wave of innovation, driving stakeholders to rethink therapeutic strategies and investment priorities.

This executive summary synthesizes the current market dynamics shaping bronchiectasis pharmacotherapy, outlining transformative trends, regulatory and economic challenges, segmentation insights, regional variations, and competitive forces. By navigating these elements in tandem, decision-makers can align their pipelines, partnerships, and commercial approaches to the evolving needs of patients and healthcare systems alike.

Emerging Innovations Reshaping Bronchiectasis Care

The bronchiectasis treatment paradigm is undergoing a radical shift as precision medicine takes center stage. Personalized therapies tailored to genetic, microbial, and immunologic profiles are emerging, with targeted anti-inflammatory agents and monoclonal antibodies set to refine disease management. Concurrently, the advent of inhaled antibiotic formulations offers the potential to deliver high local drug concentrations while minimizing systemic exposure, representing a significant departure from traditional oral and injectable regimens.

Another pivotal transformation arises from the integration of digital health technologies. Remote monitoring devices, artificial intelligence-driven diagnostic algorithms, and connected inhaler systems are enabling clinicians to track disease progression in real time and adjust therapy dynamically. These innovations are complemented by evolving regulatory pathways that prioritize accelerated approvals for breakthrough designations, encouraging pharmaceutical companies to engage in more ambitious early-stage collaborations and adaptive clinical trials.

Assessing the 2025 US Tariff Implications on Bronchiectasis Drugs

In 2025, the implementation of new United States tariffs on key active pharmaceutical ingredients and finished drug imports is poised to reverberate across the bronchiectasis drug supply chain. Manufacturers reliant on global sourcing for antibiotics, corticosteroids, and specialized biologics must anticipate increased input costs. This shift compels organizations to reassess supplier relationships, contract terms, and manufacturing footprints to safeguard margins while maintaining product accessibility.

Moreover, healthcare payers and providers will face upward pressure on reimbursement rates as expenses escalate. Forward-looking companies are already evaluating strategies to mitigate cost pass-through, including vertical integration of production capabilities and strategic stockpiling of critical components. At the same time, policymakers and industry consortia are convening to explore tariff exemptions for essential respiratory therapies, underscoring the vital need for coordinated advocacy and risk management.

Segment Dynamics Driving Bronchiectasis Treatment Modalities

A nuanced understanding of market segmentation is fundamental to capitalizing on emerging opportunities in bronchiectasis therapeutics. When viewed through the lens of drug type, the landscape comprises anti-inflammatory agents, antibiotics, bronchodilators, and mucolytics. Within anti-inflammatory strategies, corticosteroids and nonsteroidal anti-inflammatory drugs each play distinctive roles in modulating airway inflammation, while bronchodilation efforts are strengthened by long-acting and short-acting formulations that address both chronic maintenance and acute relief.

Route of administration further delineates treatment pathways, spanning inhaled therapies, oral formulations, and injectable options. Injectable treatments are subdivided into intravenous infusions, often employed during severe exacerbations, and subcutaneous injections, which offer more flexible dosing outside of hospital settings. Across all delivery modes, patient age groups-from pediatric to adult to geriatric populations-exhibit distinct pharmacokinetic and safety considerations, driving tailored dosing regimens and formulation choices.

Adding further granularity, the disease manifests in cylindrical or tubular presentations as well as varicose or cystic forms, each influencing drug deposition, mucociliary clearance, and infection risk. Finally, distribution channels encompassing hospital pharmacies, online pharmacies, and retail pharmacies shape patient access and adherence, with each channel demanding specific supply chain strategies and patient support initiatives.

Regional Market Landscapes for Bronchiectasis Therapies

Geographic markets for bronchiectasis therapies reveal varied maturity and growth trajectories. In the Americas, the United States leads due to robust clinical research infrastructure, favorable reimbursement frameworks, and rising disease awareness. Canada and parts of Latin America exhibit growing uptake driven by improved diagnostic capacity and expanding hospital networks, though pricing pressures persist in cost-conscious health systems.

Within Europe, Middle East and Africa regions, regulatory landscapes range from centralized agencies enforcing harmonized approvals to localized requirements that can delay market entry. Western Europe benefits from advanced specialty care centers, whereas the Middle East increasingly adopts international guidelines to bolster treatment standards. Meanwhile, parts of Africa face infrastructure and funding challenges, prompting stakeholders to collaborate on scalable delivery models that can bridge urban and rural access gaps.

The Asia-Pacific region presents a dynamic mix of established markets such as Japan and emerging economies including China, India and Southeast Asia. Innovation hubs in Japan emphasize next-generation inhaled therapies and biologics development, while China’s regulatory reforms have accelerated approvals for both domestic and multinational compounds. In rapidly urbanizing markets, increasing pollution-related respiratory risks and expanding private healthcare sectors underscore significant potential for bronchiectasis drug adoption.

Competitive Landscape of Key Industry Players

The competitive environment in the bronchiectasis space features a blend of global pharmaceutical conglomerates, specialty biotech firms, and generic drug manufacturers. Large multinationals bring deep development expertise and extensive trial networks, advancing pipeline assets from discovery through late-stage studies. Specialty companies often focus on niche pathways, pursuing first-in-class mechanisms such as novel anti-inflammatory biologics or innovative mucociliary clearance enhancers.

In parallel, generic producers and contract manufacturing organizations play a critical role in ensuring treatment affordability and supply continuity. Strategic alliances between these entities and research-driven firms aim to balance innovation with broad market access. Observing partnerships, licensing agreements, and acquisitions offers insight into how companies are positioning themselves to navigate patent cliffs, optimize portfolio synergies, and scale manufacturing to meet evolving demand.

Strategic Imperatives for Driving Market Leadership

Industry leaders must adopt a multifaceted strategy to thrive amid intensifying competition and regulatory complexity. Prioritizing investment in precision medicine platforms and companion diagnostics will enhance patient stratification and streamline clinical trial success. Simultaneously, diversifying manufacturing bases and fostering supplier partnerships can mitigate tariff-related cost volatility and fortify the supply chain.

Collaboration with payers and healthcare providers is equally vital. Designing value-based contracting models and real-world evidence initiatives can demonstrate therapeutic benefits while aligning pricing with clinical outcomes. Embracing digital engagement tools-such as remote monitoring, telehealth services, and patient support apps-will differentiate offerings by improving adherence and enabling continuous care beyond the clinic.

Finally, pursuing geographic expansion into under-penetrated regions calls for adaptive market entry tactics. Customized regulatory strategies, localized pricing frameworks, and culturally attuned education campaigns will unlock growth in emerging markets, positioning frontrunners to capture long-term share and cultivate sustainable patient impact.

Robust Research Framework and Analytical Rigor

This report integrates a rigorous blend of secondary research, expert interviews, and proprietary data analysis. Secondary sources include peer-reviewed journals, regulatory filings, clinical trial registries, and healthcare databases to ensure a comprehensive baseline of market knowledge. Semi-structured interviews with key opinion leaders, industry executives, and payers provide qualitative validation and nuanced perspectives on emerging trends.

Quantitative insights derive from a curated database encompassing product approvals, patent landscapes, and distribution statistics. Data triangulation methods cross-verify findings across multiple inputs to enhance accuracy and reliability. All methodologies adhere to best practices in market research, including ethical sourcing, transparency in assumptions, and peer review checkpoints prior to final synthesis.

Synthesis of Bronchiectasis Drug Market Insights

Through this executive summary, the bronchiectasis drugs market has been examined from multiple vantage points, illustrating how innovation, economic forces, and competitive dynamics converge to shape future opportunities. Key shifts in targeted therapies and digital integration herald a new era of personalized care, while tariff considerations underscore the importance of resilient supply chains.

Regional nuances and segmentation insights reveal where unmet needs persist and how tailored approaches can maximize patient outcomes. By synthesizing these insights, stakeholders are equipped to refine their strategic roadmaps, align investments with emerging trends, and deliver therapies that address the complex demands of bronchiectasis management.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Type
    • Anti-Inflammatory Agents
      • Corticosteroids
      • NSAIDs
    • Antibiotics
    • Bronchodilators
      • Long-Acting Bronchodilators
      • Short-Acting Bronchodilators
    • Mucolytics
  • Route Of Administration
    • Inhalation
    • Injection
      • Intravenous
      • Subcutaneous
    • Oral
  • Patient Demographics
    • Adult
    • Geriatric
    • Pediatric
  • Bronchiectasis Type
    • Cylindrical (Tubular)
    • Varicose (Cystic)
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AdvaCare Pharma
  • Armata Pharmaceuticals
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Insmed Incorporated
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Renovion, Inc.
  • Sanofi S.A.
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • ZAMBON COMPANY S.P.A.
  • Zydus Group

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bronchiectasis Drugs Market, by Drug Type
8.1. Introduction
8.2. Anti-Inflammatory Agents
8.2.1. Corticosteroids
8.2.2. NSAIDs
8.3. Antibiotics
8.4. Bronchodilators
8.4.1. Long-Acting Bronchodilators
8.4.2. Short-Acting Bronchodilators
8.5. Mucolytics
9. Bronchiectasis Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.3. Injection
9.3.1. Intravenous
9.3.2. Subcutaneous
9.4. Oral
10. Bronchiectasis Drugs Market, by Patient Demographics
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Bronchiectasis Drugs Market, by Bronchiectasis Type
11.1. Introduction
11.2. Cylindrical (Tubular)
11.3. Varicose (Cystic)
12. Bronchiectasis Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Bronchiectasis Drugs Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Bronchiectasis Drugs Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Bronchiectasis Drugs Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AdvaCare Pharma
16.3.2. Armata Pharmaceuticals
16.3.3. AstraZeneca PLC
16.3.4. Bayer AG
16.3.5. Boehringer Ingelheim International GmbH
16.3.6. Cipla Limited
16.3.7. F. Hoffmann-La Roche AG
16.3.8. GlaxoSmithKline PLC
16.3.9. Glenmark Pharmaceuticals Limited
16.3.10. Insmed Incorporated
16.3.11. Lupin Limited
16.3.12. Merck & Co., Inc.
16.3.13. Mylan Inc. by Viatris Inc.
16.3.14. Nephron Pharmaceuticals Corporation
16.3.15. Novartis AG
16.3.16. Perrigo Company PLC
16.3.17. Pfizer Inc.
16.3.18. Renovion, Inc.
16.3.19. Sanofi S.A.
16.3.20. Steris Healthcare Pvt. Ltd.
16.3.21. Sun Pharmaceutical Industries Limited
16.3.22. Teva Pharmaceutical Industries Ltd.
16.3.23. Verona Pharma PLC
16.3.24. ZAMBON COMPANY S.P.A.
16.3.25. Zydus Group
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BRONCHIECTASIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. BRONCHIECTASIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. BRONCHIECTASIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRONCHIECTASIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 62. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 63. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 65. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 66. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 104. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 105. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 107. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 108. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 109. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 112. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 113. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 115. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 116. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 117. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 120. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 128. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 129. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 131. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 132. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 133. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 136. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 144. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 152. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 168. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 176. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 177. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 179. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 180. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 181. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 199. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 200. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 201. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 202. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 204. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 205. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 206. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 209. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 210. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 212. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 213. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 216. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 217. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 218. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 222. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 225. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 226. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 228. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 229. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 234. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 236. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 237. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 238. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 249. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 250. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 252. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 253. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 254. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 273. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 274. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 276. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 278. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 280. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 281. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 282. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 284. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 285. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 286. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 288. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 289. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 290. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 292. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 293. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 294. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 296. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 320. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 321. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 322. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 324. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 325. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2030 (USD MILLION)
TABLE 326. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 328. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Bronchiectasis Drugs market report include:
  • AdvaCare Pharma
  • Armata Pharmaceuticals
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Insmed Incorporated
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Renovion, Inc.
  • Sanofi S.A.
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • ZAMBON COMPANY S.P.A.
  • Zydus Group

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.65 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.58 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Bronchiectasis Drugs Market 2024-2028 - Product Image

Bronchiectasis Drugs Market 2024-2028

  • Report
  • 174 Pages
  • Global
From
Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 203 Pages
  • Global
From
Non-Cystic Fibrosis Bronchiectasis Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Non-Cystic Fibrosis Bronchiectasis Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 170 Pages +
  • Global
From
Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035 - Product Image

Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Respiratory Medicine. Lecture Notes. Edition No. 10 - Product Image

Respiratory Medicine. Lecture Notes. Edition No. 10

  • Book
  • 288 Pages

About the Bronchiectasis Drug Market

Bronchiectasis is a chronic lung disease that causes irreversible damage to the airways. It is characterized by abnormal and irreversible widening of the bronchi, leading to recurrent infections and difficulty breathing. Treatment for bronchiectasis includes antibiotics, bronchodilators, and mucolytics. Inhaled corticosteroids may also be used to reduce inflammation. The bronchiectasis drug market is a subset of the larger respiratory drug market. It is composed of drugs used to treat bronchiectasis, including antibiotics, bronchodilators, mucolytics, and inhaled corticosteroids. These drugs are used to reduce inflammation, reduce mucus production, and improve airway clearance. Some companies in the bronchiectasis drug market include GlaxoSmithKline, AstraZeneca, Merck, Novartis, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.